ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Precision Neuroscience Reports First High-Bandwidth Brain–Computer Interface Achieved Without Open Surgery

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), a leading brain–computer interface (BCI) company, today announced the publication of a study in Nature Biomedical Engineering describing the company’s high-bandwidth BCI system designed for minimally invasive delivery. The paper reports both preclinical animal studies using a novel “micro-slit” surgical technique and the first five human patients implanted with the device during standard neurosurgical procedures.

The study marks a significant advance for the BCI field. For decades, high-performance BCIs have depended on penetrating electrodes—an approach that can expose patients to surgical risk and limit adoption. Precision’s work demonstrates, for the first time, that high-resolution brain signals can be captured and used for decoding and stimulation with an array that rests safely on the brain’s surface. This combination of bandwidth and safety challenges longstanding assumptions in neuroscience and points toward a more practical, scalable path for bringing BCI technology to patients.

“Brain–computer interfaces could be life-changing for people with paralysis—helping them speak, work, and live more independently—but until now the technology has required highly invasive brain surgery,” said Benjamin Rapoport, MD, PhD, co-founder and Chief Science Officer of Precision Neuroscience. “People are told that they have to choose between brain safety and performance. Our goal was to prove that you can have both. This paper shows that it’s possible to get the same high-quality brain signals without opening the skull or piercing the brain.”

The study in Nature Biomedical Engineering details the design, preclinical validation, and early human implantation of Precision’s ultra-thin, surface-based cortical electrode array. Unlike conventional BCI systems, which rely on needle-like electrodes that penetrate brain tissue, Precision’s array rests on the brain’s surface and is designed for minimally invasive delivery. Each postage stamp-sized module contains 1,024 electrodes, and in early clinical studies researchers placed up to four modules on a patient’s brain, covering approximately 8 cm² of cortex with more than 4,000 electrodes. In animal studies, the system supported high-accuracy sensory and motor decoding as well as focal electrical stimulation. In human patients, the arrays were implanted during surgeries for other conditions, where they were used to safely record high-resolution neural activity in both asleep and awake patients.

“What makes this study so exciting is the resolution of the signals we’re getting from the brain,” said Craig Mermel, PhD, Precision’s President and Chief Product Officer and a co-author of the study. “The more detail you can capture, the better you can translate thoughts into actions—whether that’s moving a cursor, generating speech, or controlling a device. This paper shows that it’s possible to collect high-resolution data safely and at scale, which is exactly what’s needed to bring brain–computer interfaces out of the lab and into everyday clinical use.”

Since the manuscript was accepted, Precision has advanced significantly beyond the five patients reported in the paper. The company has now implanted its device in more than 50 patients and, earlier this year, received FDA clearance for up to 30-day implantation. These extended-use studies, now underway at six major medical centers across the United States, allow patients recovering from neurosurgery to use Precision’s device for tasks such as typing, playing video games, or controlling robotic devices, all with their thoughts. These capabilities are expected to initially benefit people with paralysis from conditions such as spinal cord injury, stroke, or ALS.

To read the full study, visit https://www.nature.com/articles/s41551-025-01501-w  

About Precision Neuroscience
Precision Neuroscience is working to provide breakthrough treatments for the millions of people worldwide suffering from neurological illness. The company is building the only brain–computer interface designed to be minimally invasive, safely removable, and capable of processing large volumes of data. To learn more about how Precision is connecting human intelligence and artificial intelligence, visit www.precisionneuro.io.

Media Contact:
media@precisionneuro.io


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  223.23
-2.96 (-1.31%)
AAPL  274.69
-3.59 (-1.29%)
AMD  211.26
+0.48 (0.23%)
BAC  55.44
+0.30 (0.54%)
GOOG  307.90
-2.62 (-0.84%)
META  650.15
+5.92 (0.92%)
MSFT  474.09
-4.44 (-0.93%)
NVDA  177.43
+2.41 (1.38%)
ORCL  184.35
-5.62 (-2.96%)
TSLA  477.59
+18.63 (4.06%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.